Harrow Inc. (HROW)
NASDAQ: HROWHealthcareDrug Manufacturers - Specialty & GenericUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
HROW stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.15B
- Forward P/E
- 11.04
- EPS (TTM)
- -$0.99
- Dividend yield
- None
- 52-week range
- 28.54 – 54.85
- Day range
- 29.90 – 31.11
- Volume / Avg
- 707.62K / 552.72K
- Beta
- —
- Shares outstanding
- 37.49M
52-week range
HROW stock today
Shares of Harrow (HROW) finished higher on Oct 7 at $30.62, a gain of 0.89% or $0.27 per share, versus the S&P 500's 0.22% decline. At this level, HROW sits near the bottom of its 52-week range of $28.54 to $54.85: 44.2% below the high, set on Jan 7, 2026 and 7.3% above the low. HROW is down 37.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 26.9%.
Harrow has posted a net loss over the last twelve months (EPS of -$0.99), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Harrow
Company profileHarrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Mark L. Baum J.D.
- Headquarters
- Nashville, TN
- Employees
- 373
- Website
- harrow.com
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$65.00+112.28%
- Strong buy 0
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Harrow peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMPHAmphastar Pharmaceuticals Inc. | 25.54 | -1.43% | $1.09B | vs HROW |
| CRONCronos Group Inc. | 3.24 | -1.37% | $1.19B | vs HROW |
| PCRXPacira BioSciences Inc. | 25.20 | +1.78% | $1.00B | vs HROW |
| PAHCPhibro Animal Health Corporation Class A | 37.72 | +3.03% | $1.53B | vs HROW |
| COLLCollegium Pharmaceutical Inc. | 21.93 | +0.23% | $713.94M | vs HROW |
| ETONEton Pharmaceuticals Inc. | 54.88 | +0.20% | $1.57B | vs HROW |
| IRWDIronwood Pharmaceuticals Inc. Class A | 3.75 | +3.31% | $619.65M | vs HROW |
| AQSTAquestive Therapeutics Inc. | 4.62 | +0.22% | $579.86M | vs HROW |
Indexes, lists and sector
Appears in lists
Harrow stock FAQ
What is Harrow's stock price today?
HROW last traded at $30.62 as of Oct 7, 4:00 PM EDT, up 0.89% on the day. Prices are delayed at least 15 minutes.
Does Harrow pay a dividend?
No. Harrow does not currently pay a regular cash dividend.
Who is Harrow's CEO?
Mr. Mark L. Baum J.D. is the chief executive officer of Harrow Inc., which has about 373 employees.
Has HROW ever split its stock?
Yes. The most recent HROW stock split was a 1-for-5 split on Feb 8, 2013, one of 2 splits on record.
What is the HROW 52-week high?
The 52-week high for HROW is $54.85 and the 52-week low is $28.54. The stock is currently 44.2% below its high.